Ribociclib is a cyclin-dependent kinase (CDK) inhibitor used to treat hormone receptor-positive breast cancer. It works by inhibiting CDK4 and CDK6, which are essential for cancer cell proliferation. This medication is vital for managing specific types of breast cancer. In summary, Ribociclib is effective in treating hormone receptor-positive breast cancer.
Ribociclib inhibits CDK4 and CDK6, leading to cell cycle arrest and reduced proliferation of cancer cells.